Eupraxia Pharmaceuticals plans April investor presentations

Eupraxia Pharmaceuticals Inc. filed a Form 6-K highlighting upcoming investor conference participation and summarizing its drug-development focus.

Rhea-AI Filing Summary

Eupraxia Pharmaceuticals Inc. filed a Form 6-K highlighting upcoming investor conference participation and summarizing its drug-development focus. The company’s management will hold 1x1 meetings at the Raymond James Biotech Innovation Symposium on April 14, 2026 in New York.

Eupraxia will also present and host 1x1 meetings at the Bloom Burton & Co. Healthcare Investor Conference in Toronto on April 21-22, 2026, with a webcasted presentation on April 21 from 11:00AM to 11:30AM. The company is a clinical-stage biotechnology firm developing locally delivered, extended-release therapies using its proprietary Diffusphere™ micro-sphere technology.

Key Figures

Raymond James conference date: April 14, 2026 Bloom Burton conference dates: April 21-22, 2026 Bloom Burton presentation time: 11:00AM–11:30AM

3 metrics

Raymond James conference date April 14, 2026 Biotech Innovation Symposium 1x1 meetings in New York

Bloom Burton conference dates April 21-22, 2026 Healthcare Investor Conference in Toronto

Bloom Burton presentation time 11:00AM–11:30AM Webcasted company presentation on April 21, 2026

Key Terms

clinical-stage biotechnology company, Diffusphere™, Phase 1b/2 trial, Phase 2b clinical trial, +1 more

5 terms

clinical-stage biotechnology company financial

"a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology"

Diffusphere™ technical

"Diffusphere™, a proprietary, polymer-based micro-sphere technology, is designed to facilitate targeted drug delivery"

Phase 1b/2 trial medical

"EP-104GI is currently in a Phase 1b/2 trial, the RESOLVE trial, for the treatment of EoE."

Phase 2b clinical trial medical

"Eupraxia also completed a Phase 2b clinical trial (SPRINGBOARD) of EP-104IAR"

A phase 2b clinical trial is a mid-stage medical study that tests whether a new treatment works and which dose is best by enrolling a larger group of patients than earlier phase 2 studies. For investors, its results are a key signal of a drug’s real-world effectiveness and safety, and can strongly influence the chances of later regulatory approval, future funding needs, and a company’s stock outlook—like a larger pilot test before full rollout.

primary endpoint medical

"The trial met its primary endpoint and three of the four secondary endpoints."

The primary endpoint is the single main result a clinical study is designed to measure to decide if a treatment works, like the finish line in a race that tells you who won. Investors care because meeting or missing this goal drives regulatory decisions, future sales expectations and stock value — it turns trial data into a clear yes-or-no signal about a drug’s commercial prospects.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Eupraxia Pharmaceuticals (EPRX) announce in this Form 6-K?

Eupraxia Pharmaceuticals announced that its management will present and participate in upcoming investor conferences in April 2026, highlighting its clinical-stage pipeline and Diffusphere™ drug-delivery technology to institutional and healthcare-focused investors in New York and Toronto.

Which investor conferences will Eupraxia Pharmaceuticals (EPRX) attend in April 2026?

Eupraxia will join the Raymond James Biotech Innovation Symposium on April 14, 2026 in New York for 1x1 meetings, and the Bloom Burton & Co. Healthcare Investor Conference in Toronto on April 21-22, 2026 for a presentation and additional 1x1 investor meetings.

When is Eupraxia Pharmaceuticals’ Bloom Burton conference webcast scheduled?

Eupraxia’s webcasted presentation at the Bloom Burton & Co. Healthcare Investor Conference is scheduled for April 21, 2026 from 11:00AM to 11:30AM, allowing remote investors to hear management discuss the company’s technology, programs, and development strategy.

What is Eupraxia Pharmaceuticals’ Diffusphere™ technology?

Diffusphere™ is Eupraxia’s proprietary polymer-based micro-sphere technology designed for targeted, local, extended-release drug delivery. It aims to maintain stable drug levels at specific tissues, potentially reducing adverse events compared with traditional delivery methods that cause peaks and troughs in drug exposure.

Which clinical programs are currently highlighted in Eupraxia Pharmaceuticals’ pipeline?

Eupraxia highlights EP-104GI, in a Phase 1b/2 RESOLVE trial for eosinophilic esophagitis, and EP-104IAR, which completed a Phase 2b SPRINGBOARD trial in knee osteoarthritis pain and met its primary endpoint and three of four secondary endpoints.

In which therapeutic areas is Eupraxia Pharmaceuticals (EPRX) developing treatments?

Eupraxia is developing locally delivered, extended-release products for pain and inflammatory gastrointestinal disease, and sees potential for its Diffusphere™ technology in other joint indications, oncology, infectious disease, and additional critical disease areas where improved safety and tolerability are important.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/14/2026 - 07:12 PM EDT Learn about SEC filing dates

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of April 2026

Commission File Number: 001-41923

EUPRAXIA PHARMACEUTICALS INC.
(Exact name of Registrant as specified in its charter)

N/A
(Translation of Registrant’s name)

201-2067 Cadboro Bay Road
Victoria, British Columbia, Canada V8R 5G4
Telephone: (250) 590-3968 
(Address and telephone number of registrant’s principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F [   ]      Form 40-F [ X ]

DOCUMENTS INCLUDED AS PART OF THIS REPORT

Exhibit
99.1		Press Release dated April 13, 2026

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	EUPRAXIA PHARMACEUTICALS INC.
Date: April 14, 2026	By:	/s/ Alex Rothwell
		Name: Alex Rothwell
		Title: Chief Financial Officer

EXHIBIT 99.1

Eupraxia Pharmaceuticals to Present at Upcoming Investor Conferences

VICTORIA, British Columbia, April 13, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to optimize local, controlled drug delivery for applications with significant unmet need, today announced that the Company’s management team will present and participate at the following upcoming investor conferences:

Raymond James Biotech Innovation Symposium
Format: 1x1 Meetings
Date: April 14, 2026
Location: New York, NY

2026 Bloom Burton & Co. Healthcare Investor Conference
Format: Presentation & 1x1 Meetings
Date: April 21 - 22, 2026
Presentation Date & Time: April 21^st at 11:00AM - 11:30AM ET
Location: Toronto, ON
Webcast link: https://event.summitcast.com/view/7Mc8ivebFGUgA8YD45rSGK/448mWk34qHYzUoRiwSkQpa

About Eupraxia Pharmaceuticals Inc.

Eupraxia is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. Diffusphere™, a proprietary, polymer-based micro-sphere technology, is designed to facilitate targeted drug delivery of both existing and novel drugs. The technology is designed to support extended duration of effect and delivery of drugs in a hyper-localized fashion, targeting only the tissues that physicians are wanting to treat. We believe the potential for fewer adverse events may be achieved through the precision targeting and the stable and flat delivery of the active ingredient when using the Diffusphere™ technology, versus the peaks and troughs seen with more traditional drug delivery methods.

The precision of Eupraxia's Diffusphere™ technology platform has the potential to augment and transform existing FDA-approved drugs to improve their safety, tolerability, efficacy and duration of effect. The potential uses in therapeutic areas may go beyond pain and inflammatory gastrointestinal disease, where Eupraxia currently is developing advanced treatments, to also be applicable in oncology, infectious disease and other critical disease areas.

Eupraxia's EP-104GI is currently in a Phase 1b/2 trial, the RESOLVE trial, for the treatment of EoE. EP-104GI is administered as an injection into the esophageal wall, providing local delivery of drug. This is a unique treatment approach for EoE. Eupraxia also completed a Phase 2b clinical trial (SPRINGBOARD) of EP-104IAR for the treatment of pain due to knee osteoarthritis. The trial met its primary endpoint and three of the four secondary endpoints. In addition, Eupraxia is developing a pipeline of later and earlier-stage long-acting formulations. Potential pipeline indications include candidates for other inflammatory joint indications and oncology, each designed to improve on the activity and tolerability of currently approved drugs. For further details about Eupraxia, please visit the Company's website at: www.eupraxiapharma.com.

For investor and media inquiries, please contact:

James Meikle, Eupraxia Pharmaceuticals Inc.
236.330.7084
jmeikle@eupraxiapharma.com

or

Kevin Gardner, on behalf of:
Eupraxia Pharmaceuticals Inc.
617.283.2856
kgardner@lifesciadvisors.com

SOURCE Eupraxia Pharmaceuticals Inc.

Filing Exhibits & Attachments

1 document

Press Releases

• EX-99.1 PRESS RELEASE 4.3 KB